About us 

ADVANTEST was established in 1998, under the name Oncotest Ltd., and managed by Dr. Lior Soussan-Gutman.

Oncotest's mission was to facilitate a more effective approach to treatment of malignant diseases via an integrated & comprehensive approach to the diagnosis, prognosis and predictive behavior of cancer. These services were provided through leading laboratories in the US.

In 2003 Oncotest's activities were purchased by Teva Pharmaceutical Industries in Israel and became the Oncotest-Teva service unit, managed by Dr. Lior Soussan-Gutman.

Oncotest-Teva provided a full line of carefully selected laboratory tests, designed to tailor treatment to the unique characteristics of both patients and their disease.

2007 saw the extension of Oncotest-Teva's activity to additional sectors, becoming a part of ADVANTEST, with activity focusing on Hereditary syndromes (risk assessment) ; Early Detection ; Treatment Optimization ;  and Pharmacogenetics.

ADVANTEST’s current activities include providing an extended basket of services in clinical oncology in addition to new services in other fields such as cardiovascular diseases and diabetes.